guest ::
| Home > Publications database > Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. > print |
| Home > Publications database > Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. > print |
| 001 | 277081 | ||
| 005 | 20240229155009.0 | ||
| 024 | 7 | _ | |a 10.1007/s11764-021-01160-1 |2 doi |
| 024 | 7 | _ | |a pmid:35088246 |2 pmid |
| 024 | 7 | _ | |a 1932-2259 |2 ISSN |
| 024 | 7 | _ | |a 1932-2267 |2 ISSN |
| 024 | 7 | _ | |a altmetric:121751329 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-01265 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a van Leeuwen, Marieke |0 0000-0003-1976-5831 |b 0 |
| 245 | _ | _ | |a Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2023 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1687527811_13683 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.Fifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.The QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.The availability of this questionnaire will facilitate a standardized and robust assessment of the HRQOL of disease-free cancer survivors. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cancer survivor |2 Other |
| 650 | _ | 7 | |a Disease-free |2 Other |
| 650 | _ | 7 | |a Health-related quality of life |2 Other |
| 650 | _ | 7 | |a Oncology |2 Other |
| 650 | _ | 7 | |a Patient reported outcomes |2 Other |
| 650 | _ | 7 | |a Survivorship questionnaire |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Quality of Life |2 MeSH |
| 650 | _ | 2 | |a Cancer Survivors |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Survivorship |2 MeSH |
| 650 | _ | 2 | |a Surveys and Questionnaires |2 MeSH |
| 700 | 1 | _ | |a Kieffer, Jacobien M |b 1 |
| 700 | 1 | _ | |a Young, Teresa E |b 2 |
| 700 | 1 | _ | |a Annunziata, Maria Antonietta |b 3 |
| 700 | 1 | _ | |a Arndt, Volker |0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0 |b 4 |u dkfz |
| 700 | 1 | _ | |a Arraras, Juan Ignacio |b 5 |
| 700 | 1 | _ | |a Autran, Didier |b 6 |
| 700 | 1 | _ | |a Hani, Hira Bani |b 7 |
| 700 | 1 | _ | |a Chakrabarti, Manas |b 8 |
| 700 | 1 | _ | |a Chinot, Olivier |b 9 |
| 700 | 1 | _ | |a Cho, Juhee |b 10 |
| 700 | 1 | _ | |a da Costa Vieira, Rene Aloisio |b 11 |
| 700 | 1 | _ | |a Darlington, Anne-Sophie |b 12 |
| 700 | 1 | _ | |a Debruyne, Philip R |b 13 |
| 700 | 1 | _ | |a Dirven, Linda |b 14 |
| 700 | 1 | _ | |a Doege, Daniela |0 P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b |b 15 |u dkfz |
| 700 | 1 | _ | |a Eller, Yannick |b 16 |
| 700 | 1 | _ | |a Eichler, Martin |b 17 |
| 700 | 1 | _ | |a Fridriksdottir, Nanna |b 18 |
| 700 | 1 | _ | |a Gioulbasanis, Ioannis |b 19 |
| 700 | 1 | _ | |a Hammerlid, Eva |b 20 |
| 700 | 1 | _ | |a van Hemelrijck, Mieke |b 21 |
| 700 | 1 | _ | |a Hermann, Silke |0 P:(DE-He78)a8ce1da94e91296e574e4849cfabd230 |b 22 |u dkfz |
| 700 | 1 | _ | |a Husson, Olga |b 23 |
| 700 | 1 | _ | |a Jefford, Michael |b 24 |
| 700 | 1 | _ | |a Johansen, Christoffer |b 25 |
| 700 | 1 | _ | |a Kjaer, Trille Kristina |b 26 |
| 700 | 1 | _ | |a Kontogianni, Meropi |b 27 |
| 700 | 1 | _ | |a Lagergren, Pernilla |b 28 |
| 700 | 1 | _ | |a Lidington, Emma |b 29 |
| 700 | 1 | _ | |a Lisy, Karolina |b 30 |
| 700 | 1 | _ | |a Morag, Ofir |b 31 |
| 700 | 1 | _ | |a Nordin, Andy |b 32 |
| 700 | 1 | _ | |a Al Omari, Amal S H |b 33 |
| 700 | 1 | _ | |a Pace, Andrea |b 34 |
| 700 | 1 | _ | |a De Padova, Silvia |b 35 |
| 700 | 1 | _ | |a Petranovia, Duska |b 36 |
| 700 | 1 | _ | |a Pinto, Monica |b 37 |
| 700 | 1 | _ | |a Ramage, John |b 38 |
| 700 | 1 | _ | |a Rammant, Elke |b 39 |
| 700 | 1 | _ | |a Reijneveld, Jaap |b 40 |
| 700 | 1 | _ | |a Serpentini, Samantha |b 41 |
| 700 | 1 | _ | |a Sodergren, Sam |b 42 |
| 700 | 1 | _ | |a Vassiliou, Vassilios |b 43 |
| 700 | 1 | _ | |a Leeuw, Irma Verdonck-de |b 44 |
| 700 | 1 | _ | |a Vistad, Ingvild |b 45 |
| 700 | 1 | _ | |a Young, Teresa |b 46 |
| 700 | 1 | _ | |a Aaronson, Neil K |b 47 |
| 700 | 1 | _ | |a van de Poll-Franse, Lonneke V |b 48 |
| 700 | 1 | _ | |a QLG, EORTC |b 49 |e Collaboration Author |
| 773 | _ | _ | |a 10.1007/s11764-021-01160-1 |g Vol. 17, no. 4 |0 PERI:(DE-600)2388888-X |n 4 |p 1111-1130 |t Journal of cancer survivorship |v 17 |y 2023 |x 1932-2259 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:277081 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)a8ce1da94e91296e574e4849cfabd230 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-09 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-09 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1180 |2 StatID |b Current Contents - Social and Behavioral Sciences |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0130 |2 StatID |b Social Sciences Citation Index |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-25 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CANCER SURVIV : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-25 |
| 920 | 1 | _ | |0 I:(DE-He78)C071-20160331 |k C071 |l C071 Cancer Survivorship |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)M110-20160331 |k M110 |l M110 Epidemiologisches Krebsregister BW |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C071-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)M110-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|